The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://nanniecjiz088933.blog5.net/87419905/retatrutide-vs-tirzepatide-a-comparative-analysis